Arnold & Porter recently advised Banyan BioInnovations ("Banyan Bio") in its launch as an investment firm. At the time of its launch, announced on May 5, 2026, Banyan Bio had secured more than $100 million in initial commitments from life sciences investors, including ICON plc, a clinical research organization.
The new firm, staffed by more than 50 drug developers and dealmakers and powered by life sciences investment bank Locust Walk Capital, LLC, will identify clinical-stage drug assets, form NewCos around them, and provide development support. For its assets, Banyan Bio will lead due diligence, planning, and strategy, and will offer operations, regulatory, and CMC advice.
The Arnold & Porter team was led by partner Todd Boudreau and included partners Simon Firth and Alyssa Hogan, associate Peter Klopfenstein, senior attorney Greg Caramenico, and attorney and advisor Brandon Alexander. Partner David Sausen and counsel Gus Weinkam advised on tax matters.